Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ear stimulation device offers new hope for Parkinson's tremors

NCT ID NCT07400731

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called EarStim that gently stimulates the ear to temporarily improve movement problems in people with Parkinson's disease. About 90 adults with moderate to severe Parkinson's who experience 'off' episodes will try the device in a clinic and later at home for 90 days. The goal is to see if it safely reduces symptoms like stiffness and tremors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

44 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients fulfilling the following criteria are eligible for participation: * Subject must be ≥44 years of age. * Subject has PD and is on stable carbidopa/levodopa therapy for at least four weeks prior to enrollment in the study. * Subject must be willing and able to refrain from changing PD medications or dosages during the 90-day study. * Subject reports experiencing both "ON" and "OFF" episodes (MDS-UPDRS Part IV - Time Spent in the OFF-state score ≥1), as assessed and determined by the investigator. \*This corresponds to item 4.3 in MDS-UPDRS Part IV, where a score of 0 (zero) indicates that the subject experiences no OFF periods during the waking day, and a score of ≥1 reflects the presence of OFF periods at any level. * Subject experiences "OFF" periods with an "ON" score that is ≥20% better than the "OFF" score, as measured by the MDS-UPDRS Part III score, 1 hour after taking their dose of carbidopa/levodopa. * Subject has an MDS-UPDRS Part III score ≥33 in "OFF" period. * Subject agrees to remain in an "OFF" period for up to 3 hours without requiring rescue medication. * Subject can walk independently, without the use of an assisted device (e.g., cane or walker), in both "ON" and "OFF" periods. * Subject is willing to provide informed consent to participate in the study. * Subject is willing and able to comply with all study procedures and required availability for study visits. Exclusion Criteria: Patients who meet any of the following criteria are to be excluded from participation: * Subject has a medical or psychiatric comorbidity that may compromise participation in the study. * Subject has a history of cardiac rhythm disorders (e.g., atrial fibrillation, ventricular tachycardia, or atrioventricular block). * Subject is pregnant or planning to become pregnant during the course of the study. * Subject has a form of Parkinsonism other than PD, such as drug-induced Parkinsonism or Multiple System Atrophy. * Subject is currently using on-demand medications for PD, such as subcutaneous apomorphine, sublingual apomorphine, and levodopa inhalation powder. * Subject has an implanted deep brain stimulator (DBS). * Subject is receiving direct intestinal infusions of levodopa. * Subject has a history of epilepsy. * Subject's medications are expected to change during the 90-day study period. * Subject has a cardiac pacemaker, defibrillator, bladder stimulator, spinal cord stimulator, or any other active electronic medical device. * Subject is unable to understand or follow the instructions required by the study. * Subject has an ear infection or skin condition around the ear. * Subject is participating, or has participated, in another interventional clinical trial in the last 30 days that may confound the results of this study, unless approved by the Sponsor. * Subject has a history of brain surgery or peripheral neuropathy. * Subject is actively using TENS or has a history of chronic TENS use within the last 2 weeks prior to study enrollment. * Subject consumed alcohol or caffeine within 12 hours of study enrollment or has a history of alcohol dependence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Koc University Hospital

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • Şişli Hamidiye Etfal Research and Training Hospital

    NOT_YET_RECRUITING

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.